EP2046313A4 - Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie - Google Patents

Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie

Info

Publication number
EP2046313A4
EP2046313A4 EP07769053A EP07769053A EP2046313A4 EP 2046313 A4 EP2046313 A4 EP 2046313A4 EP 07769053 A EP07769053 A EP 07769053A EP 07769053 A EP07769053 A EP 07769053A EP 2046313 A4 EP2046313 A4 EP 2046313A4
Authority
EP
European Patent Office
Prior art keywords
naphtoquinones
hyperglycemia
diabetes
treatment
control
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07769053A
Other languages
English (en)
French (fr)
Other versions
EP2046313A1 (de
Inventor
Mona Wilcke
Bo Svensson
Bjoern Walse
Tore Bengtsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GLUCOX BIOTECH AB
Original Assignee
GLUCOX BIOTECH AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GLUCOX BIOTECH AB filed Critical GLUCOX BIOTECH AB
Publication of EP2046313A1 publication Critical patent/EP2046313A1/de
Publication of EP2046313A4 publication Critical patent/EP2046313A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP07769053A 2006-07-10 2007-07-06 Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie Withdrawn EP2046313A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0601503 2006-07-10
SE0602611 2006-12-04
PCT/SE2007/050507 WO2008008033A1 (en) 2006-07-10 2007-07-06 The use of naphtoquinones in the treatment and control of diabetes, insulin resistance and hyperglycemia

Publications (2)

Publication Number Publication Date
EP2046313A1 EP2046313A1 (de) 2009-04-15
EP2046313A4 true EP2046313A4 (de) 2012-01-25

Family

ID=38923504

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07769053A Withdrawn EP2046313A4 (de) 2006-07-10 2007-07-06 Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie

Country Status (2)

Country Link
EP (1) EP2046313A4 (de)
WO (1) WO2008008033A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105832717A (zh) 2008-07-25 2016-08-10 爱默蕾大学 用7,8-二羟基黄酮及其衍生物治疗各种病症
WO2012047628A2 (en) * 2010-09-27 2012-04-12 Emory University Methods of managing blood sugar levels and compositions related thereto
WO2014103321A1 (ja) * 2012-12-26 2014-07-03 学校法人北里研究所 Ｐｄｋ４阻害剤及びその利用
JP6280050B2 (ja) * 2012-12-26 2018-02-14 中島　利博 肥満症予防又は治療剤，リウマチの予防又は治療剤
KR101760565B1 (ko) 2015-06-10 2017-07-31 포항공과대학교 산학협력단 Tenc1의 활성 억제제를 유효성분으로 포함하는 당뇨병성 근위축증의 예방 또는 치료용 약학적 조성물
WO2018008984A1 (ko) * 2016-07-05 2018-01-11 이화여자대학교 산학협력단 에피디티오디옥소피페라진 화합물 또는 이의 유도체, 또는 이들의 약학적으로 허용가능한 염을 포함하는 폐동맥고혈압 예방 또는 치료용 약학적 조성물
KR102032739B1 (ko) * 2018-01-31 2019-10-16 한림대학교 산학협력단 신규한 크리신 유도체 화합물을 유효성분으로 포함하는 당뇨합병증의 예방 또는 치료용 약학 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (de) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Proteische-ADP-Ribosidierung hemmende Stoffe geeignet zum Vorbeugen der Diabetes-Mellitus-Komplikationen
EP0659883A2 (de) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 und dafür kodierende DNS
JPH1045575A (ja) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd シコニン含有ｈｓｐ４７合成抑制剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060070135A1 (en) * 1998-07-24 2006-03-30 Michel Tremblay Compositions and methods for inhibiting the enzymatic activity of PTP-1B
AU2002305926A1 (en) * 2001-02-05 2002-10-08 Exegenics Inc. Cysteine protease inhibitors
EP1435930A2 (de) * 2001-10-15 2004-07-14 National Research Council Of Canada Glykierungsinhibitoren zur prävention von komplikationen des alters, der diabetes und des rauchens
JP2005523004A (ja) * 2002-04-17 2005-08-04 グルコックス アーベー グルコース取り込みの増加及びｉｉ型糖尿病の治療のためのｎａｄ（ｐ）ｈオキシダーゼ阻害剤
KR20050036293A (ko) * 2003-10-15 2005-04-20 동아제약주식회사 나프토퀴논계 화합물을 함유한 세포질형 이소시트릭산탈수소화효소 활성 저해제 및 비만과 고지혈증 예방 또는치료용 약학적 조성물
US7067659B2 (en) * 2004-04-23 2006-06-27 Duke University Reactive oxygen generating enzyme inhibitor with nitric oxide bioactivity and uses thereof
CA2565363A1 (en) * 2004-05-06 2005-11-17 Robert F. Hofmann Use of targeted oxidative therapeutic formulation in treatment of diabetes and obesity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0638309A1 (de) * 1993-07-14 1995-02-15 ISTITUTO BIOCHIMICO ITALIANO GIOVANNI LORENZINI S.p.A. Proteische-ADP-Ribosidierung hemmende Stoffe geeignet zum Vorbeugen der Diabetes-Mellitus-Komplikationen
EP0659883A2 (de) * 1993-11-24 1995-06-28 Ono Pharmaceutical Co., Ltd. Protein p140 und dafür kodierende DNS
JPH1045575A (ja) * 1996-07-31 1998-02-17 Kureha Chem Ind Co Ltd シコニン含有ｈｓｐ４７合成抑制剤

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199817, Derwent World Patents Index; AN 1998-189155, XP002665579 *
REIKO KAMEIA ET AL: "Shikonin Stimulates Glucose Uptake in 3T3-L1 Adipocytes via an Insulin-Independent Tyrosine Kinase Pathway", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 292, no. 3, 5 April 2002 (2002-04-05), pages 642 - 651, XP008102880, ISSN: 0006-291X, [retrieved on 20020402], DOI: 10.1006/BBRC.2002.6714 *
See also references of WO2008008033A1 *

Also Published As

Publication number Publication date
WO2008008033A1 (en) 2008-01-17
EP2046313A1 (de) 2009-04-15

Similar Documents

Publication Publication Date Title
HRP20180667T1 (hr) Protutijelo agonista kloto-beta za uporabu u liječenju dijabetesa ili otpornosti na inzulin
EP2120959A4 (de) Verfahren und zusammensetzungen zur behandlung von insulinresistenz, diabetes und diabetesbedingter dyslipidämie
IL246402A (en) A therapeutic component for treating obesity, diabetes and impaired glucose tolerance
EP1758597A4 (de) Verwendung von arzneimittelkombinationen zur behandlung der insulinresistenz
GB0619860D0 (en) Treatment of insulin resistance and disorders associated therewith
HK1113289A1 (en) Composition for nutritionally improving glucose control and insulin action
IL211370A0 (en) Treatment for diabetes in patients with insufficient glycemic control desptie therapy with an oral or non-oral antidiabetic drug
IL237314A0 (en) Modified insulin polypeptides and their uses
WO2006121921A8 (en) Infusion device and method with disposable portion
IL215925A0 (en) Electrokinetically-altered fluid compositions and use thereof for treating insulin resistance and diabetes mellitus
WO2010049678A3 (en) Treatment of energy utilization diseases
EP2046313A4 (de) Verwendung von naphthochinonen bei der behandlung und kontrolle von diabetes, insulinresistenz und hyperglykämie
EP1799263A4 (de) Reduzierung von er-stress bei der behandlung von adipositas und diabetes
IL209887A0 (en) Treatment for diabetes in patients inappropriate for metformin therapy
SI1852439T1 (sl) Derivat spiroketala in njegova uporaba kot zdravilo za diabetes
PL2419097T3 (pl) Kompozycja farmaceutyczna zawierająca (1S)-1,5-anhydro-1-[5-(4-etoksybenzylo)-2-metoksy-4-metylofenylo]-1-tio-D-glucitol i metforminę oraz jej zastosowanie w leczeniu cukrzycy
ZA201000990B (en) Herbal formulations for controlling blood glucose levels in patients with diabetes
EP2000164A4 (de) Sich selbst zerstörende einwegspritze und selbstzerstörungsverfahren dafür
EP1890708A4 (de) Glucose-induzierbare insulinexpression und behandlungsmethoden für diabetes
EP2203169A4 (de) Glykämische kontrolle, diabetes-behandlung und andere behandlungen mit acetylcholinesterase-hemmern
ZA200900581B (en) Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
HK1076721A1 (en) A chinese traditional medical composition for treating diabetes and method for preparing the same
EP1872815A4 (de) Kontinuierliche subkutane insulin-infusionstherapie
WO2006007400A9 (en) Methods of diagnosing and treating obesity, diabetes and insulin resistance
HK1168283A1 (zh) 類的試劑在治療抗胰島素和相關疾病的用途

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090210

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

A4 Supplementary search report drawn up and despatched

Effective date: 20111227

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 3/08 20060101ALN20111219BHEP

Ipc: A61P 3/06 20060101ALN20111219BHEP

Ipc: A61P 3/04 20060101ALN20111219BHEP

Ipc: A61P 3/10 20060101ALI20111219BHEP

Ipc: A61K 31/37 20060101ALI20111219BHEP

Ipc: A61K 31/122 20060101AFI20111219BHEP

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130425

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160503